Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers –
-- On-track to nominate development candidate in 2024 --
BOSTON, March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
"We are excited to share preclinical proof-of-concept data for our HER3-ADC program. HER3 is a clinically validated oncology and ADC target, which is overexpressed across a range of solid tumors, and is often associated with a poor clinical outcome," said David Dornan, Ph.D., Chief Scientific Officer of Elevation Oncology. "At AACR, we plan to share preclinical proof-of-concept data highlighting our progress towards the development of a differentiated HER3-ADC. We look forward to nominating a development candidate this year and to the advancement of our HER3-ADC program toward the clinic, with the goal of improving patient outcomes."
Details of the poster presentation at AACR 2024 are as follows:
Title: Therapeutic potential of a HER3 antibody-drug conjugate for the treatment of HER3-expressing cancers
Posted In: ELEV